{
    "nct_id": "NCT05308225",
    "official_title": "A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments, including being refractory to a proteasome inhibitor, immunomodulatory agent and an anti-CD38 monoclonal antibody\n* Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample\n* Pulse oximetry ≥ 92% on room air\n* Eastern Cooperative Oncology Group (ECOG) performance of 0 - 2\n* Be willing and able to comply with the study schedule and all study requirements\n* Willing to follow contraception guidelines\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior systemic anti-tumor therapy or an investigational drug within 5 half-lives or 4 weeks of D1, whichever is shorter, preceding the first dose of study drug\n* Prior treatment with allogeneic hematopoietic stem cell transplantation within 6 months, has active graft versus host disease following transplant or currently receiving immunosuppressive therapy following transplant\n* Diagnosis of other malignancies if the malignancy required therapy in the last 3 years or is not in complete remission\n* Current history of CTCAE Grade 3 muscle paresis or ocular disorders that are Grade 3 or 2\n* Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening\n* Abnormal INR or aPTT, unless on a stable dose of an anticoagulant\n* Has ≥ Grade 3 neuropathy or Grade 2 neuropathy with associated pain\n* Has any clinically significant baseline lab results for creatinine clearance, serum aspartate aminotransferase, alanine aminotransferase, total bilirubin\n* New York Heart Association Class > 2\n* Left ventricular ejection fraction < 40%\n* Prolonged QTcF interval on a 12-lead electrocardiogram\n* Has active COVID-19 infection, and not present with symptoms within 4 weeks of study drug\n* Has an active bacterial, viral, or fungal infection\n* Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C\n* Is currently pregnant or breast feeding or planning on either during the study\n* Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation\n* Has any additional clinical history that would place the patient at an unacceptable risk if the patient participates in the study",
    "miscellaneous_criteria": ""
}